Compare TG Therapeutics Inc (TGTX) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Zeta Global Holdings Corp — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Zeta Global Holdings Corp trades at $33.09 (market cap $8.29B). The key difference: TG Therapeutics Inc and Zeta Global Holdings Corp are close in size by market cap, and Zeta Global Holdings Corp is more actively traded (7,156,795 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Zeta Global Holdings Corp for 19 Days on average.
| TGTX | ZETA | |
|---|---|---|
Market Cap | $8.16B | $8.29B |
Volume | 1,735,121 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $59.06 | $33.74 |
52-Week Low | $26.94 | $14.55 |
Typical Hold Time | 16 Days | 19 Days |
Enterprise Value | $8.37B | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
ZETA trades at $33.09, down 1.93% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and support at $32. Fundamentally, revenue grew to $1.3B in 2025 with a gross margin of 59.48%, but net income remains negative. Recent quarters saw EPS beats, and the company is expanding internationally with a new UK hub. Analyst sentiment is positive with 12 buy ratings and a $32.40 consensus target.
The outlook is cautiously optimistic due to strong revenue growth and AI-driven customer adoption, but profitability risks persist with negative net margins and high valuation multiples. Investors should weigh growth potential against execution risks and competitive pressures in the tech services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
